Get the Stockscreener App
2.11
6.64%
-0.15
After Hours:
2.11
Inhibikase Therapeutics Inc Stock (IKT) Forecast
The Inhibikase Therapeutics Inc (IKT) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $2.6048, representing a +23.45% increase from the current price of $2.11. The highest analyst price target is $2.632, and the lowest is $2.5775.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month IKT Price Target
Average 2.6897
(+27.47% Upside)
Is Inhibikase Therapeutics Inc (IKT) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 50.90 | Neutral |
| STOCH(9,6) | 69.49 | Neutral |
| STOCHRSI(14) | 79.23 | Neutral |
| MACD(12,26) | -0.039 | Buy |
| ADX(14) | 13.61 | Neutral |
| William %R | -20.83 | Neutral |
| CCI(14) | 76.24 | Neutral |
Buy: 1
Sell: 0
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.023
Buy
|
2.048
Buy
|
| MA20 |
1.9943
Buy
|
2.0555
Buy
|
| MA50 |
2.2249
Sell
|
2.1948
Sell
|
| MA100 |
2.5572
Sell
|
2.2802
Sell
|
| MA200 |
2.1199
Sell
|
2.2359
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, IKT could be considered a Neutral, with 17 technical analysis indicators signaling 5 Buy signals, 6 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on IKT, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 50.9 indicates that IKT is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 69.49 indicates that IKT is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 79.23 indicates that IKT is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 13.61 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 76.24 indicates that IKT is still overbought but not to an extreme extent.
Long-term IKT price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Inhibikase Therapeutics Inc financial reports and earnings history, Inhibikase Therapeutics Inc (IKT) stock could reach $5.7129 by 2030, $21.95 by 2040 and $12.39 by 2050. See the projected annual prices until 2050 of the Inhibikase Therapeutics Inc stock below:
- Inhibikase Therapeutics Inc (IKT) is expected to reach an average price of $4.6618 in 2035, with a high prediction of $4.685 and a low estimate of $4.5264. This indicates an $120.94% rise from the last recorded price of $2.11.
- Inhibikase Therapeutics Inc (IKT) stock is projected to chart a bullish course in 2040, with an average price target of $21.97, representing an $941.06% surge from its current level. The forecast ranges from a conservative $22.00 to a sky-high $21.95.
- Our analysts predict Inhibikase Therapeutics Inc (IKT) to jump 858.00% by 2045, soaring from $20.34 to an average price of $20.21, potentially reaching $20.65. While $20.34 is the low estimate, the potential upside is significant.
- Inhibikase Therapeutics Inc (IKT) stock is expected to climb by 2050, reaching an average of $12.45, a $489.85% jump from its current level. However, a wide range of estimates exists, with high and low targets of $12.39 and $12.45, respectively, highlighting the market's uncertainty.
Inhibikase Therapeutics Inc Stock (IKT) Year by Year Forecast
Inhibikase Therapeutics Inc Stock (IKT) Price Forecast for 2025
Inhibikase Therapeutics Inc Stock (IKT) is expected to reach an average price of $2.7088 in 2025, with a high prediction of $2.9917 and a low estimate of $2.4259. This indicates an +28.38% rise from the last recorded price of $2.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| May, 2025 | $2.7093 | $2.5775 | $2.632 | +28.40% |
| June, 2025 | $2.5783 | $2.7665 | $2.6765 | +22.19% |
| July, 2025 | $2.8845 | $2.8744 | $2.7928 | +36.71% |
| August, 2025 | $2.9536 | $3.0136 | $2.8891 | +39.98% |
| September, 2025 | $2.4727 | $2.6027 | $2.5709 | +17.19% |
| October, 2025 | $2.759 | $2.4999 | $2.609 | +30.76% |
| November, 2025 | $2.812 | $2.8962 | $2.9917 | +33.27% |
| December, 2025 | $2.8201 | $2.8098 | $2.7753 | +33.66% |
Inhibikase Therapeutics Inc Stock (IKT) Price Forecast for 2026
The predicted value for Inhibikase Therapeutics Inc (IKT) in 2026 is set at an average of $2.301. Estimates vary from a peak of $2.7236 to a trough of $1.8785, indicating an +9.05% surge from the present price of $2.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $2.7013 | $2.7334 | $2.7236 | +28.02% |
| February, 2026 | $2.5271 | $2.6851 | $2.6151 | +19.77% |
| March, 2026 | $2.4326 | $2.4658 | $2.4701 | +15.29% |
| April, 2026 | $2.3677 | $2.3877 | $2.3685 | +12.21% |
| May, 2026 | $2.3846 | $2.3868 | $2.3363 | +13.01% |
| June, 2026 | $2.3959 | $2.4039 | $2.5314 | +13.55% |
| July, 2026 | $2.4572 | $2.4593 | $2.4082 | +16.45% |
| August, 2026 | $2.181 | $2.279 | $2.3844 | +3.37% |
| September, 2026 | $1.9874 | $2.0774 | $2.0257 | -5.81% |
| October, 2026 | $1.9928 | $1.9791 | $1.9603 | -5.56% |
| November, 2026 | $2.0078 | $1.9583 | $1.9055 | -4.84% |
| December, 2026 | $1.8391 | $1.8785 | $1.9628 | -12.84% |
Inhibikase Therapeutics Inc Stock (IKT) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Inhibikase Therapeutics Inc (IKT) is $1.1701, with a high forecast of $2.3233 and a low forecast of $0.017. This indicates an -44.54% decrease from the last price of $2.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $1.6498 | $1.6958 | $1.7492 | -21.81% |
| February, 2027 | $1.3401 | $1.7044 | $1.6157 | -36.49% |
| March, 2027 | $0.3638 | $0.2211 | $1.4428 | -82.76% |
| April, 2027 | $0.0448 | $0.018 | $0.5665 | -97.88% |
| May, 2027 | $0.3343 | $0.017 | $0.593 | -84.16% |
| June, 2027 | $0.9407 | $0.6688 | $0.9184 | -55.42% |
| July, 2027 | $0.7696 | $0.7958 | $0.9161 | -63.53% |
| August, 2027 | $0.7544 | $0.8086 | $0.7514 | -64.24% |
| September, 2027 | $0.2249 | $0.3048 | $0.4159 | -89.34% |
| October, 2027 | $1.5415 | $0.0619 | $2.3233 | -26.94% |
| November, 2027 | $0.757 | $0.637 | $1.9215 | -64.12% |
| December, 2027 | $0.9607 | $0.5307 | $1.1752 | -54.47% |
Inhibikase Therapeutics Inc Stock (IKT) Price Forecast for 2028
In 2028, Inhibikase Therapeutics Inc (IKT) is projected to reach an average price of $3.8663, with a high projection of $7.5982 and a low estimate of $0.1344. This indicates an +83.24% rise from the last price of $2.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $0.8616 | $0.7862 | $1.1982 | -59.16% |
| February, 2028 | $4.24 | $0.1344 | $1.30 | +100.95% |
| March, 2028 | $3.8026 | $4.2425 | $3.9536 | +80.22% |
| April, 2028 | $4.8207 | $3.7641 | $3.6077 | +128.47% |
| May, 2028 | $4.3133 | $4.641 | $4.5394 | +104.42% |
| June, 2028 | $5.1313 | $4.9977 | $4.6224 | +143.19% |
| July, 2028 | $4.8294 | $5.2959 | $5.0749 | +128.88% |
| August, 2028 | $7.152 | $4.9785 | $7.022 | +238.96% |
| September, 2028 | $7.3301 | $7.1365 | $7.1901 | +247.40% |
| October, 2028 | $7.6982 | $7.6091 | $7.5982 | +264.84% |
| November, 2028 | $7.3208 | $7.1517 | $7.2927 | +246.96% |
| December, 2028 | $7.3388 | $7.3243 | $7.2443 | +247.81% |
Inhibikase Therapeutics Inc Stock (IKT) Price Forecast for 2029
The 2029 price forecast for Inhibikase Therapeutics Inc Stock (IKT) is $6.6235 on average, with a high prediction of $7.1634 and a low estimate of $6.0837. This represents an +213.91% increase from the previous price of $2.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $6.9414 | $6.9415 | $7.1634 | +228.98% |
| February, 2029 | $7.1195 | $6.985 | $6.836 | +237.42% |
| March, 2029 | $7.1176 | $7.0831 | $6.994 | +237.33% |
| April, 2029 | $7.1557 | $7.1311 | $6.9957 | +239.13% |
| May, 2029 | $7.0983 | $7.0191 | $6.9783 | +236.41% |
| June, 2029 | $6.5563 | $6.7963 | $6.9528 | +210.73% |
| July, 2029 | $6.4394 | $6.4299 | $6.4509 | +205.19% |
| August, 2029 | $6.917 | $6.5289 | $6.5167 | +227.82% |
| September, 2029 | $6.46 | $6.5751 | $6.7624 | +206.16% |
| October, 2029 | $6.4177 | $6.4592 | $6.3352 | +204.16% |
| November, 2029 | $6.1459 | $6.2083 | $6.2323 | +191.27% |
| December, 2029 | $5.8501 | $6.0837 | $6.0903 | +177.26% |
Inhibikase Therapeutics Inc Stock (IKT) Price Forecast for 2030
Inhibikase Therapeutics Inc Stock (IKT) is expected to reach an average price of $3.6859 in 2030, with a high forecast of $5.7129 and a low forecast of $1.6588. This signifies an +74.68% surge from the last price of $2.11.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $5.7364 | $5.7562 | $5.7129 | +171.87% |
| February, 2030 | $5.5944 | $5.5995 | $5.5996 | +165.14% |
| March, 2030 | $5.7226 | $5.538 | $5.6427 | +171.21% |
| April, 2030 | $5.4666 | $5.4797 | $5.4316 | +159.08% |
| May, 2030 | $5.2594 | $5.3283 | $5.3912 | +149.26% |
| June, 2030 | $4.9254 | $4.9802 | $5.0978 | +133.43% |
| July, 2030 | $4.665 | $4.7239 | $4.7559 | +121.09% |
| August, 2030 | $4.502 | $4.6175 | $4.5689 | +113.37% |
| September, 2030 | $4.4203 | $4.5053 | $4.5056 | +109.49% |
| October, 2030 | $4.1967 | $4.2127 | $4.3746 | +98.89% |
| November, 2030 | $4.0198 | $4.0198 | $4.0672 | +90.51% |
| December, 2030 | $1.6288 | $1.6588 | $3.9084 | -22.80% |
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):